Health Insurance · NYSE: CNC
Centene earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 5 Feb 2027
Latest: Q3 2026
Centene's Medicare Advantage turnaround reached break-even a year early, even as it narrows its 2027 MA footprint and prepares for Medicaid work requirements.
Centene's Medicare business was the standout this quarter. Medicare Advantage is now on track for break-even in 2026, a year ahead of plan, and standalone Part D performed well on disciplined bidding and scale. Marketplace pricing and moderating costs in its higher-acuity silver tier held up, while Medicaid stayed on its expected path as states trimmed rolls ahead of work requirements. Centene also decided to exit the Health Net commercial group business, largely in California.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $40.8B * |
| Q1 2025 | $46.6B |
| Q2 2025 | $48.7B |
| Q3 2025 | $49.7B |
| Q4 2025 | $49.7B * |
| Q1 2026 | $49.9B |
| Q2 2026 | $53.6B |
| Q3 2026 | $50.6B |
Data
| Q1 2025 | $2.63 |
| Q2 2025 | -$0.51 |
| Q3 2025 | -$13.50 |
| Q1 2026 | $3.11 |
| Q2 2026 | $2.19 |
| Q3 2026 | -$0.14 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 0.4% |
| Q1 2025 | 3.3% |
| Q2 2025 | -0.9% |
| Q3 2025 | -14.0% |
| Q4 2025 | -3.5% |
| Q1 2026 | 3.7% |
| Q2 2026 | 2.2% |
| Q3 2026 | -0.6% |
Data
| Q4 2024 | -$741.0M |
| Q1 2025 | $1.4B |
| Q2 2025 | $1.6B |
| Q3 2025 | $1.1B |
| Q4 2025 | $224.0M |
| Q1 2026 | $4.2B |
| Q2 2026 | $3.4B |
| Q3 2026 | -$3.9B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40.8Bd | $46.6B | $48.7B | $49.7B | $49.7Bd | $49.9B | $53.6B | $50.6B |
| Gross margin | 9.3% | 11.3% | 6.2% | 6.7% | 5.1% | 11.3% | 8.6% | 6.5% |
| Operating income | $175.0Md | $1.5B | -$458.0M | -$7.0B | -$1.7Bd | $1.9B | $1.2B | -$307.0M |
| Operating margin | 0.4% | 3.3% | -0.9% | -14.0% | -3.5% | 3.7% | 2.2% | -0.6% |
| Net income | $283.0Md | $1.3B | -$253.0M | -$6.6B | -$1.1Bd | $1.5B | $1.1B | -$71.0M |
| Diluted EPS | — | $2.63 | -$0.51 | -$13.50 | — | $3.11 | $2.19 | -$0.14 |
| Operating cash flow | -$587.0Md | $1.5B | $1.8Bd | $1.4Bd | $437.0Md | $4.4B | $3.6Bd | -$3.7B |
| Capital expenditure | $154.0Md | $135.0M | $208.0Md | $211.0Md | $213.0Md | $200.0M | $174.0Md | $194.0Md |
| Free cash flow | -$741.0M | $1.4B | $1.6B | $1.1B | $224.0M | $4.2B | $3.4B | -$3.9B |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 27 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 28 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 28 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 17 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 29 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 25 Jul 202510-Q for the period ended 30 Jun 2025SEC ↗
- 25 Apr 202510-Q for the period ended 31 Mar 2025SEC ↗
- 18 Feb 202510-K for the period ended 31 Dec 2024SEC ↗